{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:21:10Z","timestamp":1780543270456,"version":"3.54.1"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,3,17]],"date-time":"2006-03-17T00:00:00Z","timestamp":1142553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Reducing mucosal cyclo\u2010oxygenase\u20102 and prostaglandin E<jats:sub>2<\/jats:sub> production and suppressing intraoesophageal acid may be effective chemopreventive strategies in patients with Barrett's oesophagus.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To compare the effects of aspirin and rofecoxib when administered with esomeprazole on prostaglandin E<jats:sub>2<\/jats:sub> production, cyclo\u2010oxygenase\u20102 expression and proliferating cell nuclear antigen expression in patients with Barrett's oesophagus.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This exploratory, multicentre, randomized, open\u2010label, four\u2010way crossover study in 45 patients with Barrett's oesophagus evaluated prostaglandin E<jats:sub>2<\/jats:sub> content, proliferating cell nuclear antigen expression, and cyclo\u2010oxygenase\u20102 expression after 10\u2003days of sequential treatments with: esomeprazole 40\u2003mg twice daily plus aspirin 325\u2003mg once daily (E40 b.d.\u2003+\u2003A325); E40 b.d. plus rofecoxib 25\u2003mg once daily (E40 b.d.\u2003+\u2003R25); E40 b.d.; and rofecoxib 25\u2003mg once daily (R25).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Prostaglandin E<jats:sub>2<\/jats:sub> content reduction in Barrett's oesophagus tissue was significantly greater with E40 b.d.\u2003+\u2003A325 compared with E40 b.d.\u2003+\u2003R25, E40 b.d. or R25 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). All treatments containing E40 b.d. significantly decreased proliferating cell nuclear antigen expression from baseline (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). None of the treatments significantly reduced cyclo\u2010oxygenase\u20102 expression.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The combined treatment of esomeprazole 40\u2003mg b.d. and aspirin 325\u2003mg significantly decreased mucosal prostaglandin E<jats:sub>2<\/jats:sub> content and all treatments containing esomeprazole significantly reduced proliferating cell nuclear antigen expression in patients with Barrett's oesophagus.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2006.02847.x","type":"journal-article","created":{"date-parts":[[2006,3,17]],"date-time":"2006-03-17T10:06:58Z","timestamp":1142590018000},"page":"997-1005","source":"Crossref","is-referenced-by-count":17,"title":["The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E<sub>2<\/sub> production in patients with Barrett's oesophagus"],"prefix":"10.1111","volume":"23","author":[{"given":"G.","family":"TRIADAFILOPOULOS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"KAUR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"SOOD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"TRAXLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"LEVINE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"WESTON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903183401101"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01275.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.9302"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31599"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50008"},{"key":"e_1_2_6_7_2","first-page":"745","article-title":"Nonsteroidal anti\u2010inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus","volume":"11","author":"Vaughan TL","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010700400960"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03599.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70254-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90017-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02196.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30228.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05910.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080316"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2050.2003.00327.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34244"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.10.010"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00602-0"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02847.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02847.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:21:47Z","timestamp":1697426507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02847.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,17]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02847.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02847.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,17]]}}}